Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.

Doxycycline for Emphysema in People Living with HIV

Clinical Trial Details

This is a research study to evaluate if the oral medication doxycycline can slow lung damage caused by emphysema in people who also have HIV. This study will also evaluate the safety and tolerability of doxycycline.

Doxycycline is an antibiotic that was originally approved by the U.S. Food and Drug Administration (FDA) in 1967 to treat or prevent a variety of infections and conditions including bronchitis, pneumonia, certain genital infections, Lyme disease, and malaria. Because doxycycline has not been approved by the FDA to treat emphysema in people living with HIV, the use of the drug in this study is considered investigational.

Participants will be randomly assigned (like the flip of a coin) to receive either doxycycline or placebo. A placebo is a capsule that looks like doxycycline but does not contain any active medication. Participants and study staff cannot choose which drug each individual receives and there is a 50/50 chance of being assigned either option.

Participation in this study includes about 10 study visits, which may consist of chest CT scans, pulmonary function tests, walk tests, and other lab work. Participants will receive compensation for each study visit they complete. 

Key Eligibility: 

Inclusion Criteria:

  1. Individuals 30 years and older
  2. Current or former smoker
  3. Previously diagnosed with HIV 
  4. Evidence of emphysema on a cat scan of the chest

Exclusion Criteria

  1.  Inability to complete a breathing test
  2. Individuals who are pregnant, trying to get pregnant, or are currently breastfeeding
  3. Allergic or sensitivity to certain antibiotics, such as tetracyclines
  4. History of or planned lung surgery 

Detailed eligibility criteria will be discussed with the study team.

Study contact by location

Upper East Side - Manhattan

Contact(s)

Keisha Ballentine-Cargill, DNP, FNP-BC
212-746-4177
keb4006@med.cornell.edu

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:

2204024730

ClinicalTrials.gov:

05382208

Sponsor:

22-04024723/22-02-307-380/22-02-307

Status

Open to Enrollment

Age Group

Adult

Sponsor